BPC-157
vs TB-500
Two synthetic peptides studied mainly in animal injury models. Different origins, different proposed mechanisms, a similarly thin human evidence base.
BPC-157 and TB-500 are synthetic peptides with different origins and different proposed mechanisms. Most of the evidence for both comes from animals and cells. Neither has a peer-reviewed randomised trial in people, and neither is an approved medicine; the 2026 US steps on compounding are not approvals.
How do BPC-157 and TB-500 compare?
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | Synthetic 15-amino-acid peptide, reported to be a fragment of a protein found in human gastric juice | In FDA and HHS documents, a synthetic seven-amino-acid fragment of thymosin β4; what a vial sold under the name contains is shown only by its lab report |
| Origin of the research | First described in the early 1990s; 35 of 36 studies in a 2025 systematic review were preclinical | Builds on decades of thymosin β4 research; FDA staff note that thymosin β4 and TB-500 “are not the same substance” |
| Proposed mechanisms (animal/cell) | Growth-factor receptors, new blood vessels, nitric oxide; FDA staff: mechanisms “remain poorly understood” | Mostly inferred from thymosin β4 (actin binding, cell migration); in a 2024 cell study TB-500 did not differ from vehicle in closing scratch wounds |
| Main models studied | Gut, tendon, ligament, muscle and bone injury in animals | Skin wounds in aged mice (2003, unacetylated fragment); Achilles repair in rats (2026) |
| Human data | Six small studies, most without a control group; randomised data only in conference abstracts (2002–2005) | FDA found no articles in which TB-500 was given to people; one trial is registered, with no results. Published trials used the full thymosin β4 protein |
| Evidence grade | Preclinical | Preclinical |
| US status (Nov 2026) | Not an approved medicine. Advisory committee voted for 503A listing (Jul 2026), against the recommendation of FDA’s drug centre; covered by HHS’s enforcement-discretion policy (Oct 2026) | Not an approved medicine. Advisory committee voted for 503A listing (Jul 2026), against the recommendation of FDA’s drug centre; covered by HHS’s enforcement-discretion policy (Oct 2026) |
| WADA | Prohibited, S0 | Prohibited, S2 (named as a thymosin β4 derivative) |
What are the key differences between BPC-157 and TB-500?
Different parents
BPC-157 is reported to be a fragment of a protein found in gastric juice. In FDA and HHS documents, TB-500 is a fragment of thymosin β4, a protein expressed in many cell types.
Different proposed pathways
BPC-157 research centres on blood-vessel signalling and nitric oxide; thymosin β4 research centres on actin and cell migration.
Human data don't transfer
Trials of the full thymosin β4 protein, mostly as eye drops or skin gel, say nothing direct about TB-500.
Same regulatory moment
Both are among the six peptides an FDA advisory committee voted in July 2026 to add to the 503A bulks list, against the recommendation of FDA’s drug centre, and both are covered by HHS’s October 2026 enforcement-discretion policy. Neither is an approval.
Is there a controlled human study of BPC-157 and TB-500 together?
Evidence attaches to each compound on its own. We found no controlled study of the two together in people (PubMed and ClinicalTrials.gov, 18 Nov 2026).
Sources
- Vasireddi N, Hahamyan HA, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. pubmed.ncbi.nlm.nih.gov/40756949/
- U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193343/download
- Froum S, Estrin N, Pico G, et al. Case report: regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 2026;7:1907109. PMID 42876687. pubmed.ncbi.nlm.nih.gov/42876687/
- U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: TB-500-related bulk drug substances. Advisory committee briefing, 2026 (pp. 16–34); read 18 Nov 2026. www.fda.gov/media/193349/download
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther, 2012;12 Suppl 1:S37–51. pubmed.ncbi.nlm.nih.gov/22074294/
- ClinicalTrials.gov. NCT07487363: phase 1/2, randomised, placebo-controlled study of TB-500 (thymosin beta 4 17–23 fragment); search for “BPC-157” returns four records. Registry records, read 18 Nov 2026. clinicaltrials.gov/study/NCT07487363
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, 2026. hhs.gov returned 403 to our fetch on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcemen…
- Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026 (filed 28 Oct 2026); text read on govinfo 18 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.h…
- FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar, content current 6 Aug 2026. www.fda.gov/advisory-committees/advisory-committee-calendar…
- World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs read 18 Nov 2026. www.wada-ama.org/en/prohibited-list
Questions
Which one has more evidence?
Neither has a peer-reviewed randomised trial in people. BPC-157 has a larger body of animal studies, and its only randomised human data are in conference abstracts. For TB-500, FDA found no articles in which it was given to people; the human trials of thymosin β4 used the full protein and do not apply directly to TB-500.
Is there evidence for the two together?
Evidence attaches to each compound on its own. We found no controlled study of the two together in people (PubMed and ClinicalTrials.gov, 18 Nov 2026).
Is either approved?
No. Neither is an approved medicine in the US, and FDA found no approved product containing either in the countries it checked. In July 2026 an FDA advisory committee voted in favour of adding both to the 503A bulks list, against the recommendation of FDA’s drug centre, and in October 2026 HHS said it will not act against licensed pharmacies and physicians compounding them on prescription, under conditions. Neither step is an approval.